Javier Martínez-Picado is ICREA Research Professor at the AIDS Research Institute irsiCaixa in Barcelona, an institution that works to advance clinical research and translate results into patients care. He is also associate professor at the University of Vic (UVic-UCC). He received his PhD from the University of Barcelona where he subsequently became associate professor lecturing on different microbiology-related subjects. In 1996, he joined the Massachusetts General Hospital as postdoctoral fellow of the Harvard Medical School, where he engaged in AIDS research. In 2000, he obtained a position as biomedical researcher of the Spanish Health Department appointed to the Hospital "Germans Trias i Pujol" in Badalona (Barcelona). Dr. Martínez-Picado serves on different government, academic and industry advisory boards and has published extensively on HIV treatment strategies and HIV pathogenesis in international journals.
The main subject of our biomedical research is the Human Immunodeficiency Virus (HIV), a retrovirus that can lead to Acquired ImmunoDeficiency Syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. Since the beginning of the epidemic, 76 million people have been infected with HIV, of which 35 million have died from AIDS. In 2016, 1 million people died from AIDS-related causes and 1.8 million became newly infected worldwide. Our research programs are focused on understanding how HIV causes disease at the molecular and cellular level, tackling cellular and anatomical viral reservoirs, exploring new strategies to cure HIV/AIDS and collaborating on global HIV/AIDS vaccine development projects.
– Gupta RK et al. 2019, ‘HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation‘, Nature, 568, 7751, 244
– Perez-Zsolt D et al. 2019, ‘Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry‘, Nat Microbiol 4(9):1558-70.
– Julg B et al. 2019, ‘Recommendations for analytical antiretroviral treatment interruptions in HIV research trials‘, Lancet HIV 6(4):e259-68.
– Moron-Lopez S et al. 2019, ‘Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen‘, Clin Infect Dis 69(8):1320-8.
– Muncunill J et al. 2019, ‘Plasma Epstein-Barr virus load as an early biomarker and prognostic factor of HIV-1-related lymphomas‘, Clin Infect Dis 68(5):834-43.
– Jong W et al. 2019, ‘Therapeutic vaccine in chronically HIV-1-infected patients‘, Vaccines 7(4). pii: E209.
– Perez-Zsolt D et al. 2019, ‘Dendritic cells from the cervical mucosa capture and transfer HIV-1 via Siglec-1‘, Front Immunol 10, 825.
– Ruiz A et al. 2018, ‘Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells’, Front Immunol 9, 3162.
– Blanch-Lombarte O et al. 2019, ‘Enhancement of antiviral CD8+ T-cell responses and complete remission of metastatic melanoma in an HIV-1-infected subject treated with pembrolizumab‘, J Clin Med 8(12). pii:E2089
– Gonzalez-Cao M, et al. 2019. ‘Cancer immunotherapy of patients with HIV infection’, Clin Transl Oncol 21(6): 713-20.
– Millar JR, et al. 2019. ‘Increasing diagnostic uncertainties in children with in-utero HIV infection’. Pediatr Infect Dis J 38(8):e166–8.
– Mothe B, et al. 2019. ‘Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals‘. EClinicalMedicine 11:65-80.